Skip to content
Catalyst

PapersPMID:40095622

Potential Impact of Choline Alphoscerate on Depressive Symptoms in Association with Insulin Resistance in Elderly Patients with Type 2 Diabetes.

Journal of clinical medicine2025The record ↗

  1. Finding, moderate evidenceno difference foundHamilton Depression Rating Scale (HDRS) total score

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • No detected effect on Hamilton Depression Rating Scale (HDRS) total score

    moderate

    “The HDRS was significantly decreased in both the choline alphoscerate (15.9 ± 6.5 to 12.6 ± 5.8, p = 0.001) and placebo (15.4 ± 4.7 to 10.2 ± 3.9, p = 0.004) groups after 6 months, without intergroup differences (p = 0.297; Table 2).”
    Study
    RCT
    Duration
    6 months
    Interests
    Industry funded
    Dose studied
    choline alphoscerate 800 mg/day (400 mg twice daily with a meal) versus placebo
    Population
    Patients with type 2 diabetes aged 50 years or older with mild depressive symptoms (BDI 10 or more), outpatient clinic, Korea; 6-month double-blind trial, 2:1 allocation

Study record

Design
randomised controlled trial
Species
human
Population
patients with type 2 diabetes aged 50 or older with mild depressive symptoms (BDI score >= 10)
Participants
49
Comparator
placebo
Duration
183 days
Endpoints measured
23